PRECAUTIONS O
General O
: O
There O
is O
a O
possibility O
of O
increased O
absorption O
through O
ulcerated B-Not_AE_Candidate
or O
inflamed B-Not_AE_Candidate
skin I-Not_AE_Candidate
. O

Information O
for O
the O
Patient O
: O
Patients O
using O
Carac O
should O
receive O
the O
following O
information O
and O
instructions O
: O
* O
1 O
. O

This O
medication O
is O
to O
be O
used O
as O
directed O
. O

* O
2 O
. O

This O
medication O
should O
not O
be O
used O
for O
any O
disorder O
other O
than O
that O
for O
which O
it O
was O
prescribed O
. O

* O
3 O
. O

It O
is O
for O
topical O
use O
only O
. O

* O
4 O
. O

Avoid O
contact O
with O
the O
eyes O
, O
eyelids O
, O
nostrils O
, O
and O
mouth O
. O

* O
5 O
. O

Cleanse O
affected O
area O
and O
wait O
10 O
minutes O
before O
applying O
Carac O
. O

* O
6 O
. O

Wash O
hands O
immediately O
after O
applying O
Carac O
. O

* O
7 O
. O

Avoid O
prolonged O
exposure O
to O
sunlight O
or O
other O
forms O
of O
ultraviolet O
irradiation O
during O
treatment O
, O
as O
the O
intensity O
of O
the O
reaction O
may O
be O
increased O
. O

* O
8 O
. O

Most O
patients O
using O
Carac O
get O
skin B-NonOSE_AE
reactions I-NonOSE_AE
where O
the O
medicine O
is O
used O
. O

These O
reactions O
include O
redness O
, O
dryness O
, O
burning O
, O
pain O
, O
erosion O
( O
loss B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
upper I-NonOSE_AE
layer I-NonOSE_AE
of I-NonOSE_AE
skin I-NonOSE_AE
) O
, O
and O
swelling O
. O

Irritation B-NonOSE_AE
at I-NonOSE_AE
the I-NonOSE_AE
application I-NonOSE_AE
site I-NonOSE_AE
may O
persist O
for O
two O
or O
more O
weeks O
after O
therapy O
is O
discontinued O
. O

Treated O
areas O
may O
be O
unsightly O
during O
and O
after O
therapy O
. O

* O
9 O
. O

If O
you O
develop O
abdominal B-NonOSE_AE
pain I-NonOSE_AE
, O
bloody B-NonOSE_AE
diarrhea I-NonOSE_AE
, O
vomiting B-NonOSE_AE
, O
fever B-NonOSE_AE
, O
or O
chills B-NonOSE_AE
while O
on O
Carac O
therapy O
, O
stop O
the O
medication O
and O
contact O
your O
physician O
and/or O
pharmacist O
. O

* O
10 O
. O

Report O
any O
side O
effects O
to O
the O
physician O
and/or O
pharmacist O
. O

Laboratory O
Tests O
: O
To O
rule O
out O
the O
presence O
of O
a O
frank O
neoplasm B-NonOSE_AE
, O
a O
biopsy O
may O
be O
considered O
for O
those O
areas O
failing O
to O
respond O
to O
treatment O
or O
recurring O
after O
treatment O
. O

Carcinogenesis O
, O
Mutagenesis O
, O
and O
Impairment O
of O
Fertility O
: O
Adequate O
long-term O
studies O
in O
animals O
to O
evaluate O
carcinogenic B-NonOSE_AE
potential O
have O
not O
been O
conducted O
with O
fluorouracil O
. O

Studies O
with O
the O
active O
ingredient O
of O
Carac O
, O
fluorouracil O
, O
have O
shown O
positive O
effects O
in O
in O
vitro O
and O
in O
vivo O
tests O
for O
mutagenicity B-NonOSE_AE
and O
on O
impairment B-NonOSE_AE
of I-NonOSE_AE
fertility I-NonOSE_AE
in O
in O
vivo O
animal O
studies O
. O

Fluorouracil O
produced O
morphological O
transformation O
of O
cells O
in O
in O
vitro O
cell O
transformation O
assays O
. O

Morphological O
transformation O
was O
also O
produced O
in O
an O
in O
vitro O
assay O
by O
a O
metabolite O
of O
fluorouracil O
, O
and O
the O
transformed O
cells O
produced O
malignant B-NonOSE_AE
tumors I-NonOSE_AE
when O
injected O
into O
immunosuppressed B-Not_AE_Candidate
syngeneic O
mice O
. O

Fluorouracil O
has O
been O
shown O
to O
exert O
mutagenic B-NonOSE_AE
activity O
in O
yeast O
cells O
, O
Bacillus O
subtilis O
, O
and O
Drosophila O
assays O
. O

In O
addition O
, O
fluorouracil O
has O
produced O
chromosome B-NonOSE_AE
damage I-NonOSE_AE
at O
concentrations O
of O
1.0 O
and O
2.0 O
mcg/mL O
in O
an O
in O
vitro O
hamster O
fibroblast O
assay O
, O
was O
positive O
in O
a O
microwell O
mouse O
lymphoma B-NonOSE_AE
assay O
, O
and O
was O
positive O
in O
in O
vivo O
micronucleus O
assays O
in O
rats O
and O
mice O
following O
intraperitoneal O
administration O
. O

Some O
patients O
receiving O
cumulative O
doses O
of O
0.24 O
to O
1.0 O
g O
of O
fluorouracil O
parenterally O
have O
shown O
an O
increase O
in O
numerical O
and O
structural O
chromosome B-NonOSE_AE
aberrations I-NonOSE_AE
in O
peripheral O
blood O
lymphocytes O
. O

Fluorouracil O
has O
been O
shown O
to O
impair B-NonOSE_AE
fertility I-NonOSE_AE
after O
parenteral O
administration O
in O
rats O
. O

Fluorouracil O
administered O
at O
intraperitoneal O
doses O
of O
125 O
and O
250 O
mg/kg O
has O
been O
shown O
to O
induce O
chromosomal B-NonOSE_AE
aberrations I-NonOSE_AE
and O
changes B-NonOSE_AE
in I-NonOSE_AE
chromosome I-NonOSE_AE
organization I-NonOSE_AE
of I-NonOSE_AE
spermatogonia I-NonOSE_AE
in O
rats O
. O

In O
mice O
, O
single-dose O
intravenous O
and O
intraperitoneal O
injections O
of O
fluorouracil O
have O
been O
reported O
to O
kill B-NonOSE_AE
differentiated I-NonOSE_AE
spermatogonia I-NonOSE_AE
and O
spermatocytes O
at O
a O
dose O
of O
500 O
mg/kg O
and O
produce O
abnormalities B-NonOSE_AE
in I-NonOSE_AE
spermatids I-NonOSE_AE
at O
50 O
mg/kg O
. O

Pediatric O
Use O
: O
Actinic B-Not_AE_Candidate
keratosis I-Not_AE_Candidate
is O
not O
a O
condition O
seen O
within O
the O
pediatric O
population O
, O
except O
in O
association O
with O
rare O
genetic O
diseases O
. O

Carac O
should O
not O
be O
used O
in O
children O
. O

The O
safety O
and O
effectiveness O
of O
Carac O
have O
not O
been O
established O
in O
patients O
less O
than O
18 O
years O
old O
. O

Geriatric O
Use O
: O
No O
significant O
differences O
in O
safety O
and O
efficacy O
measures O
were O
demonstrated O
in O
patients O
age O
65 O
and O
older O
compared O
to O
all O
other O
patients O
. O

Pregnancy O
: O
See O
CONTRAINDICATIONS O
. O

Nursing O
Women O
: O
It O
is O
not O
known O
whether O
fluorouracil O
is O
excreted O
in O
human O
milk O
. O

Because O
many O
drugs O
are O
excreted O
in O
human O
milk O
and O
because O
of O
the O
potential O
for O
serious O
adverse O
reactions O
in O
nursing O
infants O
from O
fluorouracil O
, O
a O
decision O
should O
be O
made O
whether O
to O
discontinue O
nursing O
or O
to O
discontinue O
the O
drug O
, O
taking O
into O
account O
the O
importance O
of O
the O
drug O
to O
the O
mother O
. O

